Examples of selflessness are hard to find in today’s world.However, there are still some people in the world who think of ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

Chronic kidney disease is a common complication for people living with type 2 diabetes. Diabetes is the leading cause of ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

Chronic kidney disease (CKD) is a progressive renal disease that causes kidney function to deteriorate. It appears as urinary ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

Dialysis Centers used data from the Centers for Disease Control and Prevention to examine the prevalence of chronic diseases ...

It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.